Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007(a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients With Metastatic Breast Cancer

NCT00046527 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00046527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00046527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007(a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients With Metastatic Breast Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2001
Completion date
Not reported
Enrollment
460
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, metastases, neoplasm